2026 Michael Hallek: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	143	1491	1378	71	69	1231	88761

Research.com Recognitions

2026 - Research.com Medicine in Germany Leader Award
2023 - Research.com Medicine in Germany Leader Award
2011 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology

Overview

Michael Hallek is affiliated with the University of Cologne in Germany and specializes in the field of Medicine with a significant focus on Genetics, Pathology and Forensic Medicine, Immunology, Oncology, and Molecular Biology. Their body of work comprises 686 publications in Medicine, with subfield contributions including 191 in Genetics, 126 in Pathology and Forensic Medicine, 125 in Immunology, 81 in Oncology, and 49 in Molecular Biology.

They have contributed extensively to topics involving Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders, SARS-CoV-2 and COVID-19 Research, CAR-T cell therapy research, Advanced Breast Cancer Therapies, and Chronic Myeloid Leukemia Treatments. The count of publications per topic includes 360 on Chronic Lymphocytic Leukemia Research, 248 on Lymphoma Diagnosis and Treatment, 140 on Immunodeficiency and Autoimmune Disorders, 46 on SARS-CoV-2 and COVID-19 Research, 46 on CAR-T cell therapy research, 38 on Advanced Breast Cancer Therapies, and 36 on Chronic Myeloid Leukemia Treatments.

Frequent publication venues for Michael Hallek include Blood, Hematological Oncology, HemaSphere, Der Internist, and bioRxiv (Cold Spring Harbor Laboratory) with 75, 25, 23, 17, and 11 publications respectively.

Their frequent co-authors consist of Kirsten Fischer, Barbara Eichhorst, Stephan Stilgenbauer, Eugen Tausch, and Sandra Robrecht, reflecting a collaborative research environment.

Significant recent publications by Michael Hallek include:

"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures" (2021) in American Journal of Hematology
"Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study" (2021) in The Lancet Regional Health - Europe
"COVID-19 associated pulmonary aspergillosis" (2020) in Mycoses
"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" (2020) in Annals of Oncology
"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial" (2020) in The Lancet Oncology

Michael Hallek was awarded membership in the German National Academy of Sciences Leopoldina in 2011, recognizing contributions in Internal Medicine and Dermatology.

Best Publications

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

4504
Citations
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink

2354
Citations
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

2154
Citations
Comprehensive genomic profiles of small cell lung cancer

Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun

2106
Citations
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke

1811
Citations
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

1735
Citations
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George

1542
Citations
Mutations driving CLL and their evolution in progression and relapse.

Dan A. Landau;Eugen Tausch;Amaro N. Taylor-Weiner;Chip Stewart

1177
Citations
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus.

Georg Seisenberger;Martin U. Ried;Thomas Endreß;Hildegard Büning

1092
Citations
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer

1003
Citations
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

M Hallek;P L Bergsagel;K C Anderson

1001
Citations
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Barbara F. Eichhorst;Raymonde Busch;Georg Hopfinger;Rita Pasold

893
Citations
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

893
Citations
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer;Othman Al-Sawaf;Jasmin Bahlo;Anna Maria Fink

792
Citations
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

752
Citations
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

Thorsten Zenz;Barbara Eichhorst;Raymonde Busch;Tina Denzel

746
Citations
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Kirsten Fischer;Jasmin Bahlo;Anna Maria Fink;Valentin Goede

742
Citations
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Barbara Eichhorst;Anna-Maria Fink;Jasmin Bahlo;Raymonde Busch

702
Citations
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

Marc Beyer;Matthias Kochanek;Matthias Kochanek;Kamruz Darabi;Kamruz Darabi;Alexey Popov;Alexey Popov

665
Citations
COVID-19 associated pulmonary aspergillosis.

Philipp Koehler;Oliver A. Cornely;Bernd W. Böttiger;Fabian Dusse

549
Citations

Frequent Co-Authors

Stephan Stilgenbauer University of Ulm

Hartmut Döhner University of Ulm

Michael Kneba Kiel University

Raymonde Busch Technical University of Munich

Peter Hillmen St James's University Hospital

Hildegard Büning Hannover Medical School

Thomas J. Kipps University of California, San Diego

Martin Dreyling Ludwig-Maximilians-Universität München

Paolo Ghia Vita-Salute San Raffaele University

Andreas Engert University of Cologne

External Links

Personal website of Michael Hallek

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to a variety of other healthcare degrees and entry points. For those already working as registered nurses, affordable rn to bsn programs offer a flexible and cost-effective way to advance your nursing credentials online.

If you are switching careers and don’t have a nursing background, direct entry np programs for non nurses online allow motivated students to enter the nurse practitioner field quickly—even without prior experience.

Prospective students concerned about selectivity can look into nursing schools with high acceptance rates, which may provide greater opportunities for admission with less competitive entry requirements.

Alternatively, those interested in healthcare administration may consider medical billing and coding. If financial barriers are a concern, you might ask, can you get financial aid for medical billing and coding? Many accredited online programs offer support to make entering this field more accessible.